Clinical Trial Update: Study of a Respiratory Syncytial Virus Candidate Encapsulated in a Lipid Nanoparticle Based Formulation in Adults Aged 18 to 50 Years and 60 Years and Older [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial update reports the completion of safety and immunogenicity testing for an RSV vaccine candidate delivered in a lipid nanoparticle for…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• RSV vaccine candidate (lipid nanoparticle formulation)

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: Respiratory Syncytial Virus Immunization | Phase 1, Phase 2 | Status: COMPLETED